Xenetic Biosciences (XBIO) Price & Analysis

Compare

338 Followers

XBIO Stock Chart & Stats

$2.53

-$0.03(-0.75%)

At close: Jan 08 4:00 PM EST

$2.53

-$0.03(-0.75%)

Day’s Range― - ―

52-Week Range$2.20 - $13.93

Previous CloseN/A

Volume4.73K

Average Volume (3M)1.70M

Market Cap

$6.49M

Enterprise Value$1.27M

Total Cash (Recent Filing)$4.12M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Mar 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding2,277,139

10 Day Avg. Volume5,053,508

30 Day Avg. Volume1,695,238

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)1.02

Price to Sales (P/S)2.46

P/FCF Ratio-2.18

Enterprise Value/Market Cap0.20

Enterprise Value/Revenue0.44

Enterprise Value/Gross Profit0.44

Enterprise Value/Ebitda-0.39

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsXenetic entered a clinical trial services agreement with PeriNess to advance its DNase I-based oncology platform and lead candidate, XBIO-015, in pancreatic and colorectal cancers and potentially other advanced solid tumors.

Collaborative PartnershipsXenetic's partnership with PeriNess Ltd. is pivotal in driving forward the clinical development of its DNase I platform for various cancer treatments.

Oncology AdvancementsXenetic's entry into clinical development for advanced pancreatic cancer with DNase I marks an important step in evaluating its potential in oncology.

Bears Say

Xenetic Biosciences News

Xenetic extends R&D collaboration with The Scripps Research Institute

Xenetic (XBIO) Biosciences executed a 4-month extension of its collaboration with The Scripps Research Institute and the lab...

19d ago

XBIO

Xenetic reports Q3 EPS (33c) vs. (28c) last year

Reports Q3 revenue $1M vs. $0.6M last year. “We are steadily building the foundation for potentially transformative progress...

25d ago

XBIO

Xenetic Biosciences Reports Q3 2025 Financial Results

Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q3 earnings. Here is a breakdown of the information...

24d ago

XBIO

XBIO Upcoming Earnings Report: What to Expect?

Xenetic Biosciences, Inc. (XBIO) is scheduled to report 3rd quarter earnings on 11/14/2025. Regarding Q3 estimates, Wall Street...

26d ago

XBIO

Xenetic Biosciences Announces Public Offering Pricing

Xenetic Biosciences ( ($XBIO) ) has provided an announcement. On October 10, 2025, Xenetic Biosciences, Inc. announced the...

2M ago

XBIO

Xenetic Biosciences trading resumes

11:16 EDT Xenetic (XBIO) Biosciences trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

2M ago

XBIO

Xenetic Biosciences trading halted, volatility trading pause

11:06 EDT Xenetic (XBIO) Biosciences trading halted, volatility trading pause Published first on TheFly – the ultimate source...

2M ago

XBIO

Xenetic 735,000 share Spot Secondary priced at $6.12

Xenetic (XBIO) Biosciences announced the pricing of an underwritten offering of 735,000 shares of common stock at a...

2M ago

XBIO

Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?

Pharmaceutical stocks are soaring on Wednesday in what appears to be a continuation of yesterday’s speculative trading for...

2M ago

UPC

ACXP

Xenetic reports Q2 EPS (45c) vs. (83c) last year

Reports Q2 revenue $589,897 vs. $726,404 last year. “We continue to set a strong foundation that we believe...

4M ago

XBIO

Xenetic Biosciences Reports Improved Financial Performance

Xenetic Biosciences, Inc. ( ($XBIO) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

XBIO

Is XBIO a Buy, Before Earnings?

Xenetic Biosciences, Inc. (XBIO) is scheduled to report 2nd quarter earnings on 08/08/2025. Regarding Q2 estimates, Wall Street...

4M ago

XBIO

Xenetic says PeriNess enters clinical study agreement for DNase Platform

Xenetic (XBIO) Biosciences announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement to support...

4M ago

XBIO

Xenetic expands collaboration with The Scripps Research Institute

Xenetic (XBIO) Biosciences has continued its collaboration with The Scripps Research Institute to advance the development of the...

5M ago

XBIO

XBIO FAQ

What was Xenetic Biosciences’s price range in the past 12 months?

Xenetic Biosciences lowest stock price was $2.20 and its highest was $13.93 in the past 12 months.

What is Xenetic Biosciences’s market cap?

Xenetic Biosciences’s market cap is $6.49M.

When is Xenetic Biosciences’s upcoming earnings report date?

Xenetic Biosciences’s upcoming earnings report date is Mar 25, 2026 which is in 107 days.

How were Xenetic Biosciences’s earnings last quarter?

Xenetic Biosciences released its earnings results on Nov 14, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.16.

Is Xenetic Biosciences overvalued?

According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xenetic Biosciences pay dividends?

Xenetic Biosciences does not currently pay dividends.

What is Xenetic Biosciences’s EPS estimate?

Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Xenetic Biosciences have?

Xenetic Biosciences has 2,277,139 shares outstanding.

What happened to Xenetic Biosciences’s price movement after its last earnings report?

Xenetic Biosciences reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went up 1.167%.

Which hedge fund is a major shareholder of Xenetic Biosciences?

Currently, no hedge funds are holding shares in XBIO

Company Description

Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.